PARP1 and neoplasm: We next validated the observed sensitivity across pediatric tumor types in the GDSC2 dataset, by screening an in-house panel of 32 pediatric cancer cell lines (summarized in Supplementary Table 1) with the PARP inhibitors talazoparib and olaparib.